Seladelpar (MBX-8025; RWJ-800025) sodium salt is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist. After intraperitoneal glucose injection, blood glucose reaches ~32 mM in vehicle-treated versus ~14 mM in Seladelpar-treated foz/foz mice (P<0.05); the area under the blood glucose disappearance curve is correspondingly lower in Seladelpar-treated foz/foz mice (P<0.05). Seladelpar produces a proportionally similar effect on glucose handling in atherogenic dietfed Wt mice (P<0.05).
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|CAS Number||851528-79-5 (free base)|
|Solubility||DMSO ≥ 30 mg/mL|
|Storage||2-8°C, dry, sealed|
 Fahrettin Haczeyni, et al. Hepatol Commun. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
 Amirhossein Sahebkar, et al. Expert Opin Pharmacother. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
 Harold E Bays, et al. J Clin Endocrinol Metab. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin
|Related PPAR Products|
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
GW1929 is a potent PPAR-γ agonist, with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively.
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2.
NXT629 is an effective, selective and competitive PPAR-α antagonist. The IC50 value of HUMAN PPARα is 77 nM, which is higher than that of other nuclear hormone receptors, such as PPARδ, PPARγ, Erβ, GR and TRβ, with IC50 value of 6.0, 15, respectively. 15.2, 32.5 and >100 μM.
Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a PPARγ agonist with high affinity, activity dependent on PPARγ, inhibiting growth, IC50 is 0.8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.